The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
DNA vaccines against COVID-19: Perspectives and challenges
Open accessAbstract
The coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is associated with several fatal cases worldwide. The rapid spread of this pathogen and the increasing number of cases highlight the urgent development of vaccines. Among the technologies available for vaccine development, DNA vaccination is a promising alternative to conventional vaccines. Since its discovery in the 1990s, it has been of great interest because of its ability to elicit both humoral and cellular immune responses while showing relevant advantages regarding producibility, stability, and storage. This review aimed to summarize the current knowledge and advancements on DNA vaccines against COVID-19, particularly those in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“In fact, several preclinical studies and human clinical trials are using mRNA technology, particularly during the SARS-CoV-2 pandemic [66,67].”
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Developing Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1729069 · Cited by 1,252
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,114
Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G., Voors, A. A., Osterhaus, A. D., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5471 · Cited by 1,081
Randhawa, G. S., Soltysiak, M. P. M., El Roz, H., de Souza, C. P. E., Hill, K. A., & Kari, L. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232391 · Cited by 1,023
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997
Saavedra, J. M., Bauman, N. A., Perman, J. A., Yolken, R. H., Saavedra, J. M., Bauman, N. A., & Oung, I. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91708-6 · Cited by 970
Grifoni, A., Sidney, J., Zhang, Y., Scheuermann, R. H., Peters, B., & Sette, A. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.002 · Cited by 940
To, K. K.-W., Hung, I. F.-N., Ip, J. D., Chu, A. W.-H., Chan, W.-M., Tam, A. R., Fong, C. H.-Y., Yuan, S., Tsoi, H.-W., Ng, A. C.-K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1275 · Cited by 746
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 741
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 665
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
Wan, Y., Shang, J., Sun, S., Tai, W., Chen, J., Geng, Q., He, L., Chen, Y., Wu, J., Shi, Z., et al. (2020) · Journal of Virology · doi:10.1128/jvi.02015-19 · Cited by 662
A decade after SARS: strategies for controlling emerging coronaviruses
Graham, R. L., Donaldson, E. F., & Baric, R. S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3143 · Cited by 655
Immunogenicity of a DNA vaccine candidate for COVID-19
Smith, T. R. F., Patel, A., Ramos, S., Elwood, D., Zhu, X., Yan, J., Gary, E. N., Walker, S. N., Schultheis, K., Purwar, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16505-0 · Cited by 601
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525
COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning
Ong, E., Wong, M. U., Huffman, A., & He, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01581 · Cited by 499
The promise of mRNA vaccines: a biotech and industrial perspective
Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498 · cited 1×
“Thus, the mode of application and effectiveness of mRNA vaccines may be increased [65].”
DNA Vaccines—How Far From Clinical Use?
Hobernik, D., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113605 · Cited by 457
Next-generation vaccine platforms for COVID-19
van Riel, D., & de Wit, E. (2020) · Nature Materials · doi:10.1038/s41563-020-0746-0 · Cited by 374
Abd El-Aziz, T. M., & Stockand, J. D. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104327 · Cited by 363
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
Molecular mechanisms for enhanced DNA vaccine immunogenicity
Li, L., & Petrovsky, N. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1124762 · Cited by 335
Emerging Concepts and Technologies in Vaccine Development
Brisse, M., Vrba, S. M., Kirk, N., Liang, Y., & Ly, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583077 · Cited by 323
Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)
Calina, D., Docea, A., Petrakis, D., Egorov, A., Ishmukhametov, A., Gabibov, A., Shtilman, M., Kostoff, R., Carvalho, F., Vinceti, M., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4596 · Cited by 318
Modjarrad, K., Roberts, C. C., Mills, K. T., Castellano, A. R., Paolino, K., Muthumani, K., Reuschel, E. L., Robb, M. L., Racine, T., Oh, M.-D., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30266-x · Cited by 307
Srinivasan, S., Cui, H., Gao, Z., Liu, M., Lu, S., Mkandawire, W., Narykov, O., Sun, M., & Korkin, D. (2020) · Viruses · doi:10.3390/v12040360 · Cited by 257
Muthumani, K., Falzarano, D., Reuschel, E. L., Tingey, C., Flingai, S., Villarreal, D. O., Wise, M., Patel, A., Izmirly, A., Aljuaid, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7462 · Cited by 251
Enayatkhani, M., Hasaniazad, M., Faezi, S., Gouklani, H., Davoodian, P., Ahmadi, N., Einakian, M. A., Karmostaji, A., & Ahmadi, K. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1756411 · Cited by 250
Historical evidence for economic effects of COVID-19
Ceylan, R. F., Ozkan, B., & Mulazimogullari, E. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01206-8 · Cited by 240
Vaccines for COVID-19: The current state of play
Koirala, A., Joo, Y. J., Khatami, A., Chiu, C., & Britton, P. N. (2020) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2020.06.010 · Cited by 236
Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus
Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L., & Tan, W. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01781 · Cited by 224
Mubarak, A., Alturaiki, W., & Hemida, M. G. (2019) · Journal of Immunology Research · doi:10.1155/2019/6491738 · Cited by 199
The future of human DNA vaccines
Li, L., Saade, F., & Petrovsky, N. (2012) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2012.08.012 · Cited by 181
Roper, R. L., & Rehm, K. E. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.43 · Cited by 180
Amawi, H. A., Deiab, G. A., Aljabali, A. A. A., Dua, K., & Tambuwala, M. M. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0035 · Cited by 173
Yamin, M. (2020) · International Journal of Information Technology · doi:10.1007/s41870-020-00466-0 · Cited by 161
Xiong, X., Tortorici, M. A., Snijder, J., Yoshioka, C., Walls, A. C., Li, W., McGuire, A. T., Rey, F. A., Bosch, B., & Veesler, D. (2017) · Journal of Virology · doi:10.1128/jvi.01628-17 · Cited by 158
de Alwis, R., Chen, S., Gan, E. S., & Ooi, E. E. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102768 · Cited by 143
Quinlan, B. D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A., Parcells, M. S., Luo, G., Li, W., Zhong, G., et al. (2020) · doi:10.1101/2020.04.10.036418 · Cited by 140
Albini, A., Guardo, G. D., Noonan, D. M., & Lombardo, M. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02364-6 · Cited by 139
COVID-19 human challenge studies: ethical issues
Jamrozik, E., & Selgelid, M. J. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30438-2 · Cited by 138
DNA vaccines for targeting bacterial infections
Ingolotti, M., Kawalekar, O. U., Shedlock, D. J., Muthumani, K., & Weiner, D. B. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.57 · Cited by 136
Vaccination strategies to combat novel corona virus SARS-CoV-2
Pandey, S. C., Pande, V., Sati, D., Upreti, S., & Samant, M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117956 · Cited by 131
Emerging viruses and current strategies for vaccine intervention
Afrough, B., Dowall, S., & Hewson, R. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13295 · Cited by 128
Liu, J., Kjeken, R., Mathiesen, I., & Barouch, D. H. (2008) · Journal of Virology · doi:10.1128/jvi.02564-07 · Cited by 127
Kang, H., Wang, Y., Tong, Z., & Liu, X. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26114 · Cited by 121
Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach
Ahammad, I., & Lira, S. S. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.213 · Cited by 118
Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?
Covián, C., Retamal-Díaz, A. R., Bueno, S. M., & Kalergis, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00970 · Cited by 117
Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines
Shih, H., Wu, C.-J., Tu, Y., & Chi, C. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.05.021 · Cited by 115
A Review of DNA Vaccines Against Influenza
Lee, L., Izzard, L., & Hurt, A. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01568 · Cited by 113
Deng, X., John, S. E. S., Osswald, H. L., O’Brien, A., Banach, B. S., Sleeman, K., Ghosh, A. K., Mesecar, A. D., & Baker, S. C. (2014) · Journal of Virology · doi:10.1128/jvi.01528-14 · Cited by 100
COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
Khuroo, M. S., Khuroo, M. S., Khuroo, M. S., Sofi, A. A., & Khuroo, N. S. (2020) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.06.003 · Cited by 99
Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein
Alamri, S. S., Abbas, A. T., Siddiq, L. A., Alghamdi, A., Sanki, M. A., Al‐Muhanna, M. K., Alhabbab, R. Y., Azhar, E. I., Li, X., & Hashem, A. M. (2017) · Scientific Reports · doi:10.1038/srep44875 · Cited by 93
Will we see protection or reinfection in COVID-19?
Ota, M. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0316-3 · Cited by 93
Xu, Y., Yuen, P.-W., & Lam, J. K. W. (2014) · Pharmaceutics · doi:10.3390/pharmaceutics6030378 · Cited by 85
Computational tools for epitope vaccine design and evaluation
He, L., & Zhu, J. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.013 · Cited by 81
DNA vaccines against leptospirosis: A literature review
Silveira, M. M., Oliveira, T. L., Schuch, R. A., McBride, A. J. A., Dellagostin, O. A., & Hartwig, D. D. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.08.067 · Cited by 79
Self-citationVaccine development and therapeutic design for 2019‐nCoV/SARS‐CoV‐2: Challenges and chances
Ghaebi, M., Osali, A., Valizadeh, H., Roshangar, L., & Ahmadi, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29771 · Cited by 73
COVID-19 created chaos across the globe: Three novel quarantine epidemic models
Mishra, B. K., Keshri, A. K., Rao, Y. S., Mishra, B. K., Mahato, B., Ayesha, S., Rukhaiyar, B. P., Saini, D. K., & Singh, A. K. (2020) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2020.109928 · Cited by 70
COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials
Chakraborty, R., & Parvez, S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114184 · Cited by 70
DNA vaccines: A simple DNA sensing matter?
Coban, C., Kobiyama, K., Jounai, N., Tozuka, M., & Ishii, K. J. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25893 · Cited by 68
In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes
Moise, L., McMurry, J. A., Buus, S., Frey, S. E., Martin, W. D., & Groot, A. S. D. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.06.018 · Cited by 66
Transforming vaccine development
BLACK, S. B., Bloom, D. E., Kaslow, D. C., Pecetta, S., & Rappuoli, R. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101413 · Cited by 58
Marcotte, H., & Hammarström, L. L. G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-415847-4.00071-9 · Cited by 55
MERS-CoV vaccine candidates in development: The current landscape
Modjarrad, K. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.03.104 · Cited by 54
Synthetic DNA vaccine strategies against persistent viral infections
Villarreal, D. O., Talbott, K. T., Choo, D. K., Shedlock, D. J., & Weiner, D. B. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.33 · Cited by 52
Qing, E., & Gallagher, T. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.02.007 · Cited by 50
Covid-19: Trump sought to buy vaccine developer exclusively for US, say German officials
Dyer, O. (2020) · BMJ · doi:10.1136/bmj.m1100 · Cited by 44
Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids
Englezou, P. C., Sapet, C., Démoulins, T., Milona, P., Ebensen, T., Schulze, K., GUZMAN, C., Poulhès, F., Zelphati, O., Ruggli, N., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.04.019 · Cited by 38
Parameters predicting COVID-19-induced myocardial injury and mortality
Duerr, G. D., Heine, A., Hamiko, M., Zimmer, S., Luetkens, J. A., Nattermann, J., Rieke, G. J., Isaak, A., Jehle, J., Held, S., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118400 · Cited by 37
Albini, A., Noonan, D. M., Pelosi, G., Guardo, G. D., & Lombardo, M. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02436-7 · Cited by 30
COVID‐19 reinfection in a healthcare worker
Bongiovanni, M. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26565 · Cited by 30
Bounds, C. E., Terry, F. E., Moise, L., Hannaman, D., Martin, W. D., Groot, A. S. D., Suschak, J. J., Dupuy, L. C., & Schmaljohn, C. S. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1329788 · Cited by 28
An update on the global vaccine development for coronavirus
Rab, S., Afjal, Javaid, M., Haleem, A., & Vaishya, R. (2020) · Diabetes & metabolic syndrome · doi:10.1016/j.dsx.2020.10.023 · Cited by 26
The broad-spectrum antiviral recommendations for drug discovery against COVID-19
Hazafa, A., ur-Rahman, K., Haq, I. U., Jahan, N., Mumtaz, M., Farman, M. T., Naeem, H., Abbas, F., Naeem, M., Sadiqa, S., et al. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1770782 · Cited by 25
A review of potential treatments to date in COVID-19 patients according to the stage of the disease
Alsuliman, T., Alasadi, L., Alkharat, B., Srour, M., & Alrstom, A. (2020) · Current Research in Translational Medicine · doi:10.1016/j.retram.2020.05.004 · Cited by 20
An effective DNA vaccine platform for Middle East respiratory syndrome coronavirus
Cockrell, A. S., & Baric, R. S. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.11.40 · Cited by 7
COVID-19 Vaccines:A Race Against Time in the Middle of Death and Devastation!Preprint
Khuroo, M. S., Khuroo, M. S., Khuroo, M. S., Sofi, A. A., & Khuroo, N. (2020) · Preprints.org · doi:10.20944/preprints202005.0223.v1 · Cited by 5
Cited by
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety
Mascellino, M. T., Di Timoteo, F., De Angelis, M., & Oliva, A. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s315727 · Cited by 253
Metadata
- Authors
- Silveira, M. M., Moreira, G. M. S. G., & Mendonça, M.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 267
- Pages
- 118919
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3115622391
- Cited by
- 285
- References
- 90
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.